The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid. The validity of the patent is at the heart of patent litigation ...

The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious dispute between the company ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech traded blows this week with rival Moderna as dueling decisions came down in ...

In particular, there is an area near the 5' end of the molecule that is known as the untranslated region (UTR) or leader sequence. This portion of mRNA is located between the first nucleotide that ...

A typical bacterial mRNA transcript controlled by a riboregulatory element such as a riboswitch is composed of three sections: the 5' untranslated region (5' UTR), the protein-coding region ...

Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than traditional vaccines. Moderna successfully persuaded the court that patents it had ...